Q3 EPS Forecast for Esperion Therapeutics Raised by Analyst

Key Points

• HC Wainwright has raised its Q3 2025 earnings per share estimate for Esperion Therapeutics to ($0.11), improving from the previous estimate of ($0.16), and maintains a "Buy" rating with a price target of $16.00.
• Esperion reported $82.39 million in revenue for Q3, surpassing expectations, and posted earnings of ($0.02) per share, outperforming analyst estimates of ($0.17).
• Institutional investors own 47.39% of Esperion's stock, with JPMorgan Chase increasing its stake by 18.6% in the last quarter.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - HC Wainwright upped their Q3 2025 EPS estimates for shares of Esperion Therapeutics in a research note issued to investors on Tuesday, August 5th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings per share of ($0.11) for the quarter, up from their previous estimate of ($0.16). HC Wainwright currently has a "Buy" rating and a $16.00 price target on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics' Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.48) EPS, FY2026 earnings at $0.35 EPS, FY2027 earnings at $0.59 EPS and FY2028 earnings at $0.85 EPS.

A number of other analysts have also weighed in on the stock. Needham & Company LLC cut their target price on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen upgraded shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday. Finally, The Goldman Sachs Group cut their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $7.00.

Esperion Therapeutics Stock Performance

Shares of NASDAQ ESPR traded up $0.06 during trading hours on Friday, hitting $1.87. 5,148,622 shares of the stock were exchanged, compared to its average volume of 5,630,319. The company has a market cap of $370.63 million, a PE ratio of -3.82 and a beta of 0.82. The company's fifty day simple moving average is $1.24 and its two-hundred day simple moving average is $1.32. Esperion Therapeutics has a 1-year low of $0.69 and a 1-year high of $3.94.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.15. The business had revenue of $82.39 million for the quarter, compared to analyst estimates of $62.55 million. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%.

Institutional Trading of Esperion Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Meridian Wealth Management LLC bought a new position in shares of Esperion Therapeutics during the first quarter valued at $29,000. North Star Investment Management Corp. bought a new position in shares of Esperion Therapeutics during the second quarter valued at $25,000. Sivia Capital Partners LLC bought a new position in shares of Esperion Therapeutics during the second quarter valued at $25,000. Crestline Management LP bought a new position in shares of Esperion Therapeutics during the fourth quarter valued at $63,000. Finally, Synergy Asset Management LLC raised its stake in shares of Esperion Therapeutics by 3,496.3% during the first quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 30,138 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.